JP2024522316A5 - - Google Patents

Info

Publication number
JP2024522316A5
JP2024522316A5 JP2023572133A JP2023572133A JP2024522316A5 JP 2024522316 A5 JP2024522316 A5 JP 2024522316A5 JP 2023572133 A JP2023572133 A JP 2023572133A JP 2023572133 A JP2023572133 A JP 2023572133A JP 2024522316 A5 JP2024522316 A5 JP 2024522316A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
sequence shown
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522316A (ja
Filing date
Publication date
Priority claimed from CN202110560605.6A external-priority patent/CN115364237A/zh
Application filed filed Critical
Publication of JP2024522316A publication Critical patent/JP2024522316A/ja
Publication of JP2024522316A5 publication Critical patent/JP2024522316A5/ja
Pending legal-status Critical Current

Links

JP2023572133A 2021-05-21 2022-05-20 抗体がコンジュゲートされたリポソーム Pending JP2024522316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110560605.6A CN115364237A (zh) 2021-05-21 2021-05-21 一种偶联抗体脂质体
CN202110560605.6 2021-05-21
PCT/CN2022/094222 WO2022242763A1 (zh) 2021-05-21 2022-05-20 一种偶联抗体脂质体

Publications (2)

Publication Number Publication Date
JP2024522316A JP2024522316A (ja) 2024-06-14
JP2024522316A5 true JP2024522316A5 (https=) 2025-05-26

Family

ID=84058855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572133A Pending JP2024522316A (ja) 2021-05-21 2022-05-20 抗体がコンジュゲートされたリポソーム

Country Status (5)

Country Link
US (1) US20260115313A1 (https=)
EP (1) EP4353267A4 (https=)
JP (1) JP2024522316A (https=)
CN (1) CN115364237A (https=)
WO (1) WO2022242763A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025043547A1 (zh) * 2023-08-30 2025-03-06 杭州高田生物医药有限公司 T细胞导向免疫脂质体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011338487B2 (en) * 2010-12-06 2016-12-22 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
CN109498817B (zh) * 2017-09-14 2026-03-06 上海交通大学 一种多细胞靶向脂质体

Similar Documents

Publication Publication Date Title
Elamir et al. Ultrasound-triggered herceptin liposomes for breast cancer therapy
Pillai Nanotechnology toward treating cancer: A comprehensive review
Mahato Nanoemulsion as targeted drug delivery system for cancer therapeutics
Sapra et al. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments
Tang et al. The use of nanoparticulates to treat breast cancer
Pillai Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci 1 (2): 13
Elbayoumi et al. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies
Yi et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers
Tang et al. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
Bandekar et al. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo
JP2000510825A (ja) 標的細胞への最適内在化をもたらす免疫リポソーム
ElBayoumi et al. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice
Jha et al. Liposomal drug delivery system for cancer therapy: advancement and patents
Badrzadeh et al. Drug delivery and nanodetection in lung cancer
US20170258718A1 (en) Pharmaceutical composition, preparation and uses thereof
Kumar et al. Novel drug delivery system
JP2024522316A5 (https=)
JP2019505582A (ja) タキサンのカチオン性リポソーム製剤、タキサンの非リポソーム製剤およびさらなる活性剤の併用を用いた乳癌の治療
JP2024523127A5 (https=)
US20110027171A1 (en) Ph sensitive liposome composition
Sivadasan An updated review of stealth liposomes and its ability to evade the immune system: a new frontier in cancer chemotherapy
Wang et al. Optimization of landscape phage fusion protein-modified polymeric PEG-PE micelles for improved breast cancer cell targeting
Abu-Qudais et al. Nanomedicines in cancer therapy
Zhang Clinical applications of tumor-targeted systems